Quantcast
Last updated on April 21, 2014 at 10:27 EDT

Latest Immune Pharmaceuticals Inc. Stories

2013-11-26 00:20:38

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North"). The Company will transfer its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29, 2013, and the first day of trading on First North will be December 2, 2013. Erik Penser...

2013-11-20 00:21:10

GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 20, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) ("Immune" or the "Company") announced today its financial results for the three and nine month periods ended September 30, 2013. During the third quarter of 2013, Immune recorded net income attributable to common stockholders of $1.2 million, or $0.11 per...

2013-11-01 00:20:53

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider for the Company's common shares currently listed on NASDAQ OMX Stockholm Exchange under the trading symbol IMNP. The firm will continue to be the Company's liquidity provider after its planned transfer of its stock listing from NASDAQ OMX...

2013-10-16 00:20:40

Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 16, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Tomer Adar, M.D. at the Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University of Jerusalem, presented a poster on October 15, 2013 entitled Inhibition of Eotaxin-1 (CCL 11) Ameliorates DSS-Induced Colitis; A...

2013-10-15 00:20:32

New Members Provide strong financing and operating experience TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 15, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP), announced today that Rene Lerer, M.D., Executive Chairman of Magellan Health Services (NASDAQ: MGLN), and Daniel Kazado, Senior Advisor to Melini Capital, have agreed to join the Company's Board of Directors. Dr. Lerer and Mr. Kazado replace Pierre Albouy and Herve de Kergrohen,...

2013-10-03 00:20:11

TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and CEO, will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The presentation will take place on Wednesday, October 9, 2013 at 10:00 AM local time at the...

2013-09-30 00:21:32

Company to Transfer Swedish Listing to NASDAQ OMX First North Premier TARRYTOWN, N.Y., Sept. 30, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange and OTCQX: IMNP) ("IMMUNE" or the "Company") announced today that following the recent merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation, the Company will focus its capital raising efforts in the United States to support its objective to up-list to a U.S. national securities exchange (NASDAQ or...

2013-09-23 00:20:40

TARRYTOWN, N.Y., Sept. 23, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013 the Company's symbol for its common stock trading on the OTCQX trading platform will change to "IMNP". The Company's common stock had been required to trade under the symbol "EPCTD" since August 21, 2013 as a result of the previously implemented 1-for-40 reverse stock split. The Company's...

2013-09-04 00:20:47

TARRYTOWN, N.Y., Sept. 4, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at the 15(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City. Daniel Teper, CEO of Immune Pharmaceuticals Inc., will provide an overview of...

2013-08-27 00:22:02

New Three-Year Term Enables Focus on Product Development TARRYTOWN, N.Y., Aug. 27, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) ("Immune" or the "Company") announced today that it has executed the Third Amendment and Consent to the Loan and Security Agreement between the Company and MidCap Funding III, LLC ("MidCap"). This amendment restructures the loan in connection with the completed merger of Immune Pharmaceuticals Ltd....